Search for content and authors
 

DISUBSTITUTED INDOLO[2,3-b]QUINOLINE DERIVATIVES. THE CYTOTOXIC ACTIVITY IN VITRO AGAINST VARIOUS HUMAN TUMOR CELL LINE.

Aleksandra Nowicka 1Małgorzata Piskozub 1Joanna Wietrzyk Wojciech Łuniewski 2Łukasz S. Kaczmarek 2Wanda Peczyńska-Czoch 3

1. Polish Academy of Sciences, Institute of Immunology and Experimental Therapy (IITD), Rudolfa Weigla 12, Wrocław 53-114, Poland
2. Pharmaceutical Research Institute (IF), Rydygiera 8, Warszawa 01-793, Poland
3. Wrocław University of Technology, Department of Chemistry, Wybrzeże Wyspiańskiego 27, Wrocław 50-370, Poland

Abstract

In our study disubstituted indolo[2,3-b]quinoline derivatives bearing (dialkylamino)alkyl chains at N-6 and C-2 or C-9 position were tested against various human tumor cell lines: human colon (LoVo), uterine (MES-SA), promyelocytic leukemia (HL-60), lung (A-549) and human melanoma (Hs294T), as well as normal mouse fibroblast cell line (BALB/3T3).

We found that all indoloquinolines showed cytotoxic activity against the cells of all cancer lines used. ID50 values of tested compounds against the normal mouse fibroblast cell line (BALB/3T3) were comparable to the results obtained for the tumor cell lines. It suggests that the compounds show similar cytotoxic activity against normal and tumor cell lines.

The studied indoloquinolines were highly active against the cell of human promyelocytic leukemia (HL-60) and human uterine sarcoma cell line (MES-SA). The compound ISS-101 showed the highest of all the derivatives tested cytotoxic activity against the tumor and normal cell lines.

Table 1. Cytotoxic activity in vitro of indolo[2,3-b]quinolines against the cells of LoVo, HL-60 , MES-SA, A-549, MCF-7, Hs294T and BALB/3T3 cell lines.

tab_1.PNG

Table2. Structures of disubstituted indolo[2,3-b]quinoline derivatives.

tab 2_1.PNG

 

Legal notice
  • Legal notice:
 

Related papers

Presentation: Poster at V Multidyscyplinarna Konferencja Nauki o Leku, by Wojciech Łuniewski
See On-line Journal of V Multidyscyplinarna Konferencja Nauki o Leku

Submitted: 2006-02-01 13:27
Revised:   2009-06-07 00:44